{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-021904","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.114209+00:00","generated_at":"2026-05-15T22:35:50.906419+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting","bullets":["Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.","Phase 2 SHIMMER data showed 86% slowing of decline on NPI-12 vs placebo; no motor function worsening.","No approved medications for DLB psychosis; traditional antipsychotics are contraindicated.","Next study will use validated endpoints for neuropsychiatric symptoms; patients randomized to 100 mg zervimesine or placebo.","Company expects to meet with FDA Division of Psychiatry by midyear 2026 to discuss the program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-021904","json":"https://secwatch.observer/filing/0001104659-26-021904.json","markdown":"https://secwatch.observer/filing/0001104659-26-021904.md","text":"https://secwatch.observer/filing/0001104659-26-021904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926021904/0001104659-26-021904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926021904/tm267638d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:35:50.906419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}